Drug Trial Radar · NCT01256762
Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer
Last checked: Nov 19, 2026Latest source record: Jan 26, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
166
Actual
Start
Nov 2010
Primary completion
Oct 2012
Study completion Dec 2012
Sponsor
- Lead sponsor
- Geron CorporationIndustry
- Sponsor type
- Industry
- First posted
- Dec 9, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of treatment with imetelstat + paclitaxel (with or without bevacizumab) versus paclitaxel (with or without bevacizumab) alone for patients with locally recurrent or metastatic breast cancer who have not received chemotherapy or have received one non-taxane based chemotherapy for metastatic breast cancer.
Conditions
- Locally Recurrent or Metastatic Breast Cancer
Interventions
Imetelstat sodiumDrug
Imetelstat is administered at a dose of 300 mg/m2 on day one of a 21 day cycle.
BevacizumabDrug
Bevacizumab is administered at 15 mg/kg on day one of a 21 day cycle
PaclitaxelDrug
Paclitaxel is administered at 90 mg/m2 on days one and eight of a 21 day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survivalTime frame: Occurring post randomization through end of study period (9 mos. after the last participant is randomized)
Locations
55 sites in 2 countries. Site status is shown where the registry gives one.
Clearview Cancer Center
Huntsville, Alabama
Alta Bates Summit Medical Center
Berkeley, California
Southbay Oncology Hematology Partners
Campbell, California
Cancer Care Associates
Fresno, California
Memorial Miller Hospital
Long Beach, California
St. Joseph Hospital
Orange, California
Desert Regional Comprehensive Cancer Center
Palm Springs, California
UC San Diego
San Diego, California
Redwood Regional Medical Group
Santa Rosa, California
Univ. Colorado at Denver
Aurora, Colorado
Connecticut Oncology & Hematology
Torrington, Connecticut
Medical Oncology Hematology
Waterbury, Connecticut
Florida Oncology Associates
Jacksonville, Florida
Hematology Oncology Associates
Port Saint Lucie, Florida
H. Lee Moffitt Cancer Center
Tampa, Florida
Northeast Georgia Cancer Care
Athens, Georgia
Peachtree Hematology Oncology
Atlanta, Georgia
Emory University
Atlanta, Georgia
Northeast Georgia Medical Center
Gainesville, Georgia
Central Georgia Cancer Care
Macon, Georgia
Summit Cancer Care
Savannah, Georgia
Kootenai Medical Center
Post Falls, Idaho
Ingalls Memorial Hospital
Chicago, Illinois
Rush University
Chicago, Illinois
Mid Illinois Hematology & Oncology
Normal, Illinois
Cancer Treatment Centers of America
Zion, Illinois
Indiana University
Indianapolis, Indiana
Community Hospitals of Indiana
Indianapolis, Indiana
Horizon Oncology Center
Lafayette, Indiana
Cancer Center of Kansas
Wichita, Kansas
Montgomery Cancer Care
Mount Sterling, Kentucky
Michigan State University
East Lansing, Michigan
New Mexico Cancer Center
Albuquerque, New Mexico
Prohealth Associates
Lake Success, New York
Stony Brook University
Stony Brook, New York
Carolinas Hematology/Oncology
Charlotte, North Carolina
Moses Cone Medical System
Greensboro, North Carolina
Case Western Reserve Univ.
Cleveland, Ohio
Mercy Physicians of Oklahoma
Oklahoma City, Oklahoma
Cancer Care Associates
Tulsa, Oklahoma
Showing 40 of 55 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.